Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accounts Payables: 2010-2025

Historic Accounts Payables for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $17.7 million.

  • Arrowhead Pharmaceuticals' Accounts Payables rose 55.20% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 55.20%. This contributed to the annual value of $17.7 million for FY2025, which is 55.20% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Accounts Payables of $17.7 million as of Q3 2025, which was down 46.52% from $33.0 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Accounts Payables' 5-year high stood at $35.9 million during Q3 2023, with a 5-year trough of $796,000 in Q4 2022.
  • For the 3-year period, Arrowhead Pharmaceuticals' Accounts Payables averaged around $16.3 million, with its median value being $11.4 million (2024).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Accounts Payables crashed by 80.43% in 2022, and later skyrocketed by 1,150.56% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Accounts Payables (Quarterly) stood at $4.1 million in 2021, then plummeted by 80.43% to $796,000 in 2022, then soared by 460.30% to $4.5 million in 2023, then soared by 224.15% to $14.5 million in 2024, then spiked by 55.20% to $17.7 million in 2025.
  • Its Accounts Payables stands at $17.7 million for Q3 2025, versus $33.0 million for Q2 2025 and $10.0 million for Q1 2025.